ImmunityBio, Inc. today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line Non-small cell lung cancer (NSCLC) patients who progressed after checkpoint inhibitor therapy and standard-of-care chemotherapy. The clinical study's results... READ →
Precision Vaccinations
/ April 25th, 2024Eliminating fake vaccine news with pharmacist, nurse, and physician review.
For more articles, try our search.